Canada - English - Health Canada

natco pharma (canada) inc - imatinib (imatinib mesylate) - tablet - 400mg - imatinib (imatinib mesylate) 400mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

teva canada limited - imatinib (imatinib mesylate) - tablet - 400mg - imatinib (imatinib mesylate) 400mg - antineoplastic agents

Canada - English - Health Canada

sun pharma canada inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

sun pharma canada inc - imatinib (imatinib mesylate) - tablet - 400mg - imatinib (imatinib mesylate) 400mg - antineoplastic agents

Canada - English - Health Canada

accord healthcare inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

accord healthcare inc - imatinib (imatinib mesylate) - tablet - 400mg - imatinib (imatinib mesylate) 400mg - antineoplastic agents

Canada - English - Health Canada

mint pharmaceuticals inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

mint pharmaceuticals inc - imatinib (imatinib mesylate) - tablet - 400mg - imatinib (imatinib mesylate) 400mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - imatinib mesilate, quantity: 59.735 mg (equivalent: imatinib, qty 50 mg) - capsule, hard - excipient ingredients: gelatin; titanium dioxide; iron oxide yellow; sodium lauryl sulfate; sodium stearylfumarate; purified water; crospovidone; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; iron oxide red; ethanol absolute; ammonia - indicated for the: ,? treatment of patients with chronic myeloid leukaemia (cml) ,? treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy,? treatment of adult patients with relapsed or refractory ph+ all as monotherapy ,? treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements, where conventional therapies have failed ,? treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed ,? treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) ,? adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp). ? treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) ? adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist (see dosage and administration and clinical trials)